首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GLIPR |
| Uniprot No | P48060 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-232aa |
| 氨基酸序列 | ANILPDIENEDFIKDCVRIHNKFRSEVKPTASDMLYMTWDPALAQIAKAWASNCQFSHNTRLKPPHKLHPNFTSLGENIWTGSVPIFSVSSAITNWYDEIQDYDFKTRICKKVCGHYTQVVWADSYKVGCAVQFCPKVSGFDALSNGAHFICNYGPGGNYPTWPYKRGATCSACPNNDKCLDNLCVNRQRDQVKRYYSVVYPGWPIYPRNR |
| 预测分子量 | 28.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GLIPR重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction*
**作者**：Ren C, et al.
**摘要**：研究揭示重组GLIPR1蛋白通过泛素-蛋白酶体途径降解致癌蛋白(如c-Myc)，抑制前列腺癌细胞增殖并诱导凋亡，提示其作为肿瘤抑制因子的治疗潜力。
---
2. **文献名称**：*Recombinant GLIPR1 protein inhibits glioma growth by modulating tumor-associated macrophages*
**作者**：Huang Y, et al.
**摘要**：实验表明，重组GLIPR1蛋白通过激活STAT1通路重塑肿瘤微环境，促进巨噬细胞向抗肿瘤M1表型极化，显著抑制胶质瘤小鼠模型的肿瘤进展。
---
3. **文献名称**：*GLIPR1-delivered by exosomes suppresses hepatocellular carcinoma metastasis via PI3K/AKT pathway*
**作者**：Li X, et al.
**摘要**：该研究发现外泌体递送的重组GLIPR1蛋白可靶向抑制肝癌细胞PI3K/AKT信号通路，降低侵袭转移能力，为肝癌治疗提供新型递送策略。
---
如需更早期研究或特定疾病方向文献，可进一步补充说明。
GLIPR (Glioma Pathogenesis-Related Protein), also known as GLIPR1 or RTVP-1. is a member of the pathogenesis-related (PR) protein superfamily, initially identified for its upregulated expression in glioma tissues. Structurally, it contains a conserved N-terminal signal peptide and a C-terminal domain rich in cysteine residues, which is characteristic of PR proteins involved in stress responses and immune regulation. While PR proteins are well-studied in plants, GLIPR represents a rare example in vertebrates, with roles extending beyond pathogen defense to critical cellular processes in development and disease.
In normal physiology, GLIPR is predominantly expressed in the brain, prostate, and testes, where it regulates cell differentiation, apoptosis, and extracellular matrix interactions. Its dysregulation, however, is implicated in multiple cancers. For instance, GLIPR acts as a tumor suppressor in prostate cancer, where its expression is frequently downregulated due to promoter hypermethylation. Restoring GLIPR expression in prostate cancer models has been shown to inhibit proliferation, induce apoptosis, and suppress metastasis. Conversely, in gliomas and certain solid tumors, GLIPR may exhibit context-dependent oncogenic properties, promoting invasiveness and therapy resistance through mechanisms involving Wnt/β-catenin and AKT signaling pathways.
Recombinant GLIPR protein, produced via bacterial or mammalian expression systems, has emerged as a tool for therapeutic exploration. Preclinical studies highlight its potential in cancer immunotherapy, where it enhances dendritic cell maturation and T-cell activation. Gene therapy approaches using viral vectors to deliver GLIPR have also demonstrated antitumor efficacy in animal models. Beyond oncology, GLIPR’s role in neural development and stem cell regulation is under investigation, with implications for neurodegenerative diseases.
Despite promising applications, challenges remain in understanding its dual roles across cancer types and optimizing delivery strategies. Ongoing research focuses on elucidating structure-function relationships and evaluating clinical translatability, positioning recombinant GLIPR as a multifaceted candidate for both therapeutic and diagnostic innovation.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
